2月5日，复星医药（600196/02196）发布公告，控股子公司药品注册申请获受理。
公司控股子公司上海复星医药产业发展有限公司自主研发的复迈宁®（通用名：芦沃美替尼片）用于治疗伴有症状、无法手术的丛状神经纤维瘤的Ⅰ型神经纤维瘤病成人患者的药品上市申请已获国家药品监督管理局受理，并被纳入优先审评程序。
截至2025年12月，针对该药品的累计研发投入约为6.63亿元。根据IQVIAMIDAS最新数据，2024年，MEK1/2选择性抑制剂于全球范围的销售额约为20.68亿美元。
公司提醒，新增适应症在开展商业化前尚需获得药品注册批准，获药品注册申请受理不会对公司现阶段业绩产生重大影响。
2025年前三季度，复星医药实现收入293.93亿元，归母净利润25.23亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.